Levosimendan is approved in: (A) Hea failure, (B) Kidney failure, (C) Liver failure, (D) Endocrine crisis
Answer is A. Levosimendan is a calcium sensitizer -- it increases the sensitivity of the hea to calcium, thus increasing cardiac contractility without a rise in intracellular calcium.Has been approved for use in acute cardiac failure in EuropeKatzung 13e pg: 220